Icon Plc $ICLR Shares Sold by Napean Trading & Investment Co Singapore PTE Ltd

Napean Trading & Investment Co Singapore PTE Ltd cut its position in shares of Icon Plc (NASDAQ:ICLR) by 17.6% during the second quarter, Holdings Channel.com reports. The firm owned 23,313 shares of the medical research company’s stock after selling 4,980 shares during the quarter. Icon makes up approximately 0.9% of Napean Trading & Investment Co Singapore PTE Ltd’s portfolio, making the stock its 29th biggest position. Napean Trading & Investment Co Singapore PTE Ltd’s holdings in Icon were worth $3,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in ICLR. Sierra Legacy Group increased its holdings in shares of Icon by 15.4% during the 2nd quarter. Sierra Legacy Group now owns 4,430 shares of the medical research company’s stock worth $644,000 after buying an additional 590 shares during the last quarter. Portside Wealth Group LLC grew its position in Icon by 11.9% in the second quarter. Portside Wealth Group LLC now owns 1,816 shares of the medical research company’s stock worth $264,000 after acquiring an additional 193 shares during the period. Raiffeisen Bank International AG increased its stake in Icon by 7.1% during the second quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company’s stock worth $1,094,000 after acquiring an additional 500 shares during the last quarter. SG Americas Securities LLC raised its position in Icon by 12.3% in the second quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company’s stock valued at $2,322,000 after purchasing an additional 1,743 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Icon by 21.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after purchasing an additional 650,379 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Up 2.9%

Shares of NASDAQ:ICLR opened at $161.02 on Wednesday. The firm has a market capitalization of $13.00 billion, a PE ratio of 21.79, a price-to-earnings-growth ratio of 3.04 and a beta of 1.22. Icon Plc has a 1 year low of $125.10 and a 1 year high of $228.29. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The firm’s 50-day moving average is $174.92 and its two-hundred day moving average is $161.15.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.03. Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the previous year, the business posted $3.35 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. Analysts predict that Icon Plc will post 13.38 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ICLR shares. UBS Group set a $220.00 price target on Icon in a report on Friday, October 24th. Jefferies Financial Group cut shares of Icon from a “buy” rating to a “hold” rating and decreased their target price for the company from $220.00 to $175.00 in a research report on Tuesday, September 9th. Robert W. Baird set a $220.00 price target on shares of Icon in a research report on Friday, October 24th. Truist Financial boosted their price target on shares of Icon from $187.00 to $234.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $205.00.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.